The 2021 WHO Classification of Central Nervous System Tumors achieves refined risk stratification by elevating the prognostic weight of molecular markers (e.g., CDKN2A/B homozygous deletion directly defining grading) and incorporating novel molecularly defined tumor entities. The gene discussed is CDKN2A; the disease is central nervous system cancer.